Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Chronic kidney disease
•
Nephrology
•
Endocrinology
•
Bone and Calcium Disorders
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
Related Questions
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
How do you approach hematuria in a patient with diabetic nephropathy?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Do patients with 25 OH vitamin D levels under 20 ng/ml and normal PTH levels ("relative hypoparathyroidism") still carry a risk for bone and calcium metabolism disorders such as osteomalacia?
How would you approach management of retroperitoneal fibrosis causing ureteral compression that has already caused irreversible loss of kidney function?
What is your approach to treating immobilization hypercalcemia?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
